RA Capital — 2026 Investments

AN2 Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs from its boron chemistry platform, with a pipeline spanning hematologic diseases, infectious diseases, oncology, and bone disorders.

BiotechHealthtechMenlo Park, US

Joseph S. Zakrzewski(Co-Founder & Director)EEEric Easom(Co-Founder, President & CEO)inGeorge H. Talbot(Co-Founder & Senior Clinical Advisor)Michael R.K. (Dickon) Alley(Co-Founder, SVP Research Fellow, Head of Biology)SCSanjay Chanda(Chief Development Officer)inLOLucy O. Day(Chief Financial Officer)in

Co-investorsADAdjuvant CapitalBIBioRock VenturesFLFlucas VenturesMOMountain Group CapitalBIBiotechnology Value FundHAHatteras Venture Partners

Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.

AI & Machine LearningBiotechDeep TechMedical Devices

MMMathai Mammen(CEO, President and Chairman)in

Co-investorsARARCH Venture PartnersCACatalio Capital Management, LPFOForesite CapitalFRFrazier Life SciencesGEGeneral CatalystGVGV (Google Ventures)+9 more

Relmada is a clinical-stage biopharmaceutical company developing therapies including NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, and Sepranolone, a candidate targeting compulsive behaviors via GABAA receptor modulation.

BiotechHealthtechNew York, US

Sergio Traversa(Executive Officer, Director)Paul Kelly(Director)Maged Shenouda(Director)inEOEliseo O. Salinas(President and Chief Scientific Officer)inDouglas Beck(Chief Financial Officer)Charles Ence(Chief Accounting and Compliance Officer)

Co-investorsBIBioAdvanceBABAM ElevateBRBraidwellCOCommodore CapitalJAJanus Henderson InvestorsOROrbiMed+2 more

Solstice Oncology is a clinical-stage immuno-oncology company developing porustobart, a second-generation engineered CTLA-4 antibody given with anti–PD-1 therapy in the neoadjuvant (pre-surgery) setting to treat early-stage cancers.

BiotechHealthtechBoston, US

DFDavid Feltquate(Chief Medical Officer)inMaiken Keson-Brookes(Chief Operating Officer & General Counsel)CAROLINE LOEW(Executive Officer, Director, Promoter)Caroline J. Loew(President & Chief Executive Officer)

BoardJGJULIE GRANT(Director)in

Board seatEMEmily MinkowALAndrew Levin· per SEC Form D

Co-investorsFOForbionCACanaan Partners

Stipple Bio develops targeted oncology therapies that act on tumor-specific cell surface epitopes to expand druggable targets and improve therapeutic index for cancer patients.

BiotechHealthtechCambridge, US

ARAaron Ring(Co-founder)inAMAashish Manglik(Co-founder)inJeff Landau(Chief Executive Officer)inRGRoland Gendron(Chief Business Officer)inMZMichelle Zhang(Chief Scientific Officer)in

BoardVAVineeta Agarwala(Director)in

Board seatDDDerek DiRocco· per SEC Form D

Co-investorsANAndreessen HorowitzGVGV (Google Ventures)MAMagnetic VenturesOMOMX VenturesAXAxial VCLOLoLa Capital Partners+1 more

Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.

BiotechHealthtechNewton, US

Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Founder)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)

Co-investorsBABain Capital Life SciencesNENew Enterprise Associates (NEA)SASamsara BioCapitalSASanofi VenturesMAMass General Brigham VenturesREREDMILE+9 more

Avalanche Energy develops compact fusion technology to generate high-energy neutrons for materials testing, radioisotope production, and advanced nuclear battery systems serving defense, space, and commercial power applications.

Deep TechDefense TechEnergyRichland, US

Robin Langtry(Co-Founder, CEO)inBRBrian Riordan(Co-Founder, COO)in

BoardMNMatthew Nordan(Director)inKyle Teamey(Director)

Co-investorsCOCongruent VenturesFOFounders FundLOLowercarbon CapitalTOToyota VenturesALAlumni VenturesAUAutodesk Foundation+7 more

Vivace Therapeutics is an oncology-focused drug discovery and development company creating small-molecule inhibitors targeting the Hippo-YAP pathway to treat cancers including mesothelioma, meningioma, and various other tumor types.

BiotechHealthtechMedical DevicesSan Mateo, US

Shuang Qiao(Executive Officer, Director)Sheng Ding(Executive Officer)Sofie Qiao(Founder)

BoardEdward Hu(Director)JWJun Wu(Director)JSJake Simson(Director)in

Co-investorsCACanaan PartnersCECenova CapitalMIMission Biocapital

Avalanche provides software development tools that startups can integrate to build and operate referral programs within their products.

Enterprise SoftwareMarketing TechSan Francisco, US

E(Elezhan (Ijan) Zhakiya(Founder)inNikhil Shinday

Co-investorsLOLowercarbon CapitalY Y Combinator808090 IndustriesCOCongruent VenturesFOFounders FundTOToyota Ventures

The Avalanche Foundation is a non-profit organization that supports innovation and growth in the Avalanche ecosystem through grants, programs, and strategic support for developers, entrepreneurs, and communities building on the Avalanche blockchain platform.

Crypto & Web3Data & InfrastructureDeveloper ToolsEnterprise SoftwareFintech

EGEmin Gun Sirer(Founder)inBrian Riordan(Founder)Elezhan (Ijan) Zhakiya(Founder)inEmin Gün Sirer(Founder)Kevin Sekniqi(Founder)Maofan Ted Yin(Founder)

Co-investorsA1a16z cryptoAEAegis VentuesANAndreessen HorowitzANAndromeda CapitalBABaseTwoBIBig Brain Holdings+35 more

Ava Labs is a company building blockchain infrastructure and tools for creating and using finance applications.

Crypto & Web3Data & InfrastructureDeep TechFintechNew York City, US

EGEmin Gün Sirer(Founder)inEGEmin Gun Sirer(Founder)inCCCharley CooperinKevin Sekniqi(Founder)Maofan Ted Yin(Founder)Maofan Yin(Founder)

Co-investorsANAnimoca BrandsABAbstract VenturesCECeras VenturesCOContinue CapitalINInitialized CapitalLVLvna Capital+6 more

Celea develops deupirfenidone, a pulmonary therapeutic targeting idiopathic pulmonary fibrosis in partnership with physicians and patient advocacy organizations.

BiotechHealthtechMedical Devices

Co-investorsPUPureTech HealthLELeaps by Bayer

Climb is a French wealth management service that combines advisors with technology to grow clients' assets through an open-architecture selection of investment products (life insurance, retirement PER, real estate, private equity, tax-reduction schemes, crypto).

FintechSaaS

AEAldric Emié(CEO)in

Co-investorsKIKima VenturesALAlly Bridge GroupREREDMILE

Contraline develops new contraceptive and reproductive health technologies, with a focus on male contraception.

BiotechDigital HealthMedical DevicesCharlottesville, US

KEKevin Eisenfrats(Founder)inJohn Herr(Founder)

BoardIris Van Alderwerelt van Rosenburgh(Director)GBGurdane Bhutani(Director)inMartin J Emerson(Director)Tom Thorpe(Director)

PartnerLSLaura Stoppel· quoted

Co-investorsBIBiotechnology Value FundMBMBX CapitalALAllied Venture PartnersALAlumni VenturesAMAmboy Street VenturesAUAurum Venture Partners+19 more

Develops therapies for cardiometabolic conditions.

Co-investorsNENew Enterprise Associates (NEA)HBHBM Healthcare InvestmentsRTRTW Investments L.P.

Dignify Therapeutics is developing drug programs that induce on-demand defecation and urination to treat functional bowel and bladder disorders, including incontinence and retention associated with neurological conditions and aging.

BiotechDigital HealthMedical DevicesResearch Triangle Park, US

Edward C Burgard(Executive Officer, Director, Promoter)Karl Thor(Chief Scientific Officer)inBWBenny Ward(Executive Officer, Director, Promoter)inAnthony DiTonno(CEO)Ed Burgard(President)Jeff Welch(Chief Operating Officer)

Co-investorsESEshelman Ventures, LLCMOMontreux Equity Partners

Inhibikase Therapeutics is a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics for pulmonary arterial hypertension (PAH).

BiotechHealthtechAtlanta, US

MHMilton H. Werner Ph.D(Executive Officer, Director)inJoseph Frattaroli, C.P.A.(Executive Officer)Dennis Berman(Director)Gisele Dion(Director)

BoardPaul Grint, M.D.(Director)Roy Freeman M.D.(Director)

Karyopharm is a pharmaceutical company developing drugs based on its SINE (Selective Inhibitor of Nuclear Export) technology, with medicines targeting cancers including multiple myeloma and diffuse large B-cell lymphoma.

BiotechHealthtechNewton, US

SPStuart Poulton(Executive Officer)inMichael Mano(Executive Officer)inRRReshma Rangwala(Executive Officer)inRPRichard Paulson(CEO)inStephen Mitchener(Executive Officer)inMichael Mason(Executive Officer)in

Co-investorsAVAvoro Capital AdvisorsFOForesite CapitalHEHEALTHCARE ROYALTY PARTNERS

NorthLinks Bio is a clinical-stage biopharmaceutical company developing HEX17, an intranasal antiviral designed to prevent respiratory virus infections by blocking viral entry at the nasal epithelium.

BiotechHealthtechSt Andrews, GB

FCFanny Cavalié(Chief Executive Officer)in

Oncology Ventures is a cancer-focused venture capital fund that invests in healthcare technology startups related to oncology care.

AI & Machine LearningBiotechDigital HealthHealthtech

BFBen Freeberg(Founder, Managing Partner)inJay Freeberg(Chief Financial Officer)

Co-investorsSASandwich CapitalALAlleyCorpCACanaan PartnersCOConcord Health PartnersCVCVS Health VenturesFOForbion+5 more

The Faculty of Pharmacy and Biochemistry offers pharmacy and biochemistry degree programs, including a Pharmacy programme in English aligned with EU Directive 2005/36/EC for EU/EEA registration.

EdTech

Co-investorsVEVesna AdvisorsNENextech InvestTHThe Column Group

Pinnacle Medicines develops oral peptide-based therapies designed to deliver antibody-like efficacy in pill form for patients with chronic diseases.

BiotechDigital HealthDoylestown, US

CSChengzao Sun(Founder)inSandeep Somani(Founder)in

Co-investorsFOForesite CapitalQUQuan CapitalLALAVOROrbiMedVEVenrock

Slate Medicines is a clinical-stage biotechnology company.

BiotechMedical DevicesBoston, US

Sara Pacheco(Executive Officer)Neil Buckley(Executive Officer, Director)inGOGregory Oakes(Chief Executive Officer and Board Director)in

BoardTim Lohoff(Director)CXCindy Xiong(Director)inALAndrew Levin(Director)

Co-investorsFOForesite CapitalVEVenrock

SonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound-mediated delivery) to deliver genetic payloads to targeted sites in a redosable way.

BiotechDeep TechDigital HealthHealthtechSouth San Francisco, US

KGKenneth Greenberg(Co-Founder, President & CEO)in

Co-investorsVIVida VenturesLELeaps by BayerARARCH Venture PartnersFOFoothill VenturesILIllumina VenturesMEMedical Excellence Capital+8 more

Terremoto Biosciences is a clinical-stage biotech developing precision therapies for oncology and genetic diseases using lysine-targeted covalent chemistry.

BiotechDeep TechSouth San Francisco, US

Grace Lu(Executive Officer)James Christensen(Executive Officer, Director)Charles Baum(Executive Officer, Director)in

BoardMichael Goller(Director)RHReid Huber(Director)inPTPeter Thompson(Director)in

Co-investorsECEcoR1 CapitalOROrbiMedNONovo HoldingsTHThird Rock Ventures

Plasma is a financial technology company offering Plasma One, a stablecoin-based account and Visa card that supports USD₮ transfers, cashback, and yield through third-party DeFi protocols.

Crypto & Web3FintechLondon, GB

Co-investors1/1/1 Capital6T6th Man VenturesBEBeni Venture CapitalIMImpossible FinanceMEMercury FundMIMirana Ventures+12 more